SOURCE: Cleveland BioLabs, Inc.

May 05, 2008 08:30 ET

Cleveland BioLabs Featured in "Gene Marcial's 7 Commandments of Stock Investing"

BUFFALO, NY--(Marketwire - May 5, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that the Company has been featured in "Gene Marcial's 7 Commandments of Stock Investing," recently published by FT Press. Gene Marcial is a senior writer and columnist at BusinessWeek where he writes the column "Inside Wall Street."

Cleveland BioLabs was cited as one of "several little-known biotechs that have outscored their peers" under the chapter titled, "Commandment 6: Don't Fear The Unknown" of "Gene Marcial's 7 Commandments of Stock Investing." The chapter includes a brief summary by the author of Cleveland BioLabs' history and stock price from its IPO in July 2006 through early 2008.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release does not suggest or imply an endorsement by the Company of any recommendation or reference included in any publication by unrelated parties.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com